52North secures £4.7m co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co to advance oncology diagnostics.
The funding round was co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co.
52North is a medical technology company focused on transforming urgent care pathways in oncology through accessible patient solutions. The Cambridge-based firm develops innovative diagnostic tools designed to improve health equity and patient safety.
Cambridge-based medical technology company 52North has secured £4.7m in a funding round co-led by KHP Ventures and Cedars-Sinai Intellectual Property Co. The financing also attracted participation from OKG Capital, Cambridge Enterprise Ventures, Cancer Research Horizons, Macmillan Cancer Support, and high-net-worth angels including Jonathan Milner and Roland Diggelmann.
The capital will be directed towards advancing the company's product portfolio toward commercialisation. Key priorities include the development of the flagship Neutrocheck device for monitoring neutropenic sepsis risks, progression through the Aster platform, and the rollout of the ACORN digital platform.
The transaction marks a notable cross-border collaboration between leading hospital venture funds from the UK and the US. Alongside the equity financing, the firm also secured a $1.5m grant from the National Institute for Health and Care Research.
From the founder
"This round represents a significant leap forward for 52North. With support from both UK and US healthcare leaders, we can expand our product pipeline working with major strategic partners and appropriately leverage the latest tools including AI to reshape urgent care pathways for patients worldwide. The commitment from both KHP Ventures and Cedars-Sinai exemplifies the belief in our vision and the value of our solutions."
Umaima Ahmad
CEO at 52North
Investor perspective
"Our partnership with Cedars-Sinai reflects our shared mission to invest in and support companies that have the potential to revolutionise healthcare delivery on a global scale. We are proud to continue backing 52North as they continue to develop solutions that empower both patients and clinicians."
Tim Irish
Chair, KHP Ventures
Use of funds
- 01Continue product development
Investors
Tim Irish
KHP Ventures
Nirdesh Gupta
Cedars-Sinai Intellectual Property Co
Karim Galzahr
OKG Capital
Amanda Wooding
Cambridge Enterprise Ventures
Phil Masterson
Cancer Research Horizons
Tanya Humphreys
Macmillan Cancer Support
National Institute for Health and Care Research